Uro-DNA Collection for Expanded Genome-Wide Association Study (GWAS) of Renal Cell Carcinoma (RCC)

Overview

In the last decade, investigators from the Department of Cancer Epidemiology and Genetics (National Cancer Institute, USA) have conducted genome-wide association (GWAS) studies of renal cell carcinoma.

Dr. Mark PURDUE and Dr. Stephen CAHNOCK (Department of Epidemiology of Cancer and Genetics, NCI) propose to expand their genome-wide association study (Expanded GWAS) by genotyping approximately 10,000 additional cases of kidney cancer patients, in collaboration with US institutions, South-American and European.

This study describes the participation of the French Kidney Cancer Research Network (UroCCR) in the Expanded GWAS research, under the coordination of Professor BERNHARD (Bordeaux University Hospital).

Full Title of Study: “Uro-DNA Collection for Expanded Genome-Wide Association Study (GWAS) of Renal Cell Carcinoma (RCC) (Uro-DNA – GWAS)”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: April 2020

Detailed Description

The aim of the Expanded GWAS study is to better understand the role of common genetic variants in susceptibility to renal cell carcinoma (RCC).

The participation of the French UroCCR network consists in completing the bio-collection of the UroCCR cohort by preserving constitutional DNA and to provide DNA samples to the US NCI team.

This will increase the number of samples for meta-analysis and contribute to better identify clear cell kidney cancer susceptibility loci.

Interventions

  • Procedure: Intervention in the UroCCR sites
    • Blood sampling of a 5ml tube per patient. (for eligible patients recruited in the study, after signing the consent) DNA extraction: For the patients of Bordeaux University Hospital, 2 aliquots will be constituted: 1 aliquot for Expanded GWAS, containing at least 2 μg of DNA, 1 aliquot for the UroCCR biobank. For patients from other UroCCR centers, only 1 aliquot will be constituted: 1 aliquot for Expanded GWAS, containing at least 2 μg of DNA. Transmission of the extracted DNA samples to the Biological Resource Center (CRB) of Bordeaux.
  • Procedure: Intervention in the CRB of Bordeaux University Hospital
    • Temporary storage of DNA samples for Expanded GWAS before shipping to the NCI. Storage of samples for the DNA biobank. Overall packing of GWAS samples for shipment to the NCI. Shipping to the NCI: Constitutive DNA samples must be sent to the NCI by May 1, 2020 for inclusion in the Expanded GWAS study.
  • Procedure: Intervention at the Methodology and Data Management Centre of Bordeaux University Hospital
    • Transfer of the data associated with the samples to the NCI.
  • Procedure: Subsequent intervention at the NCI (for information)
    • Samples will be genotyped at the NCI Cancer Genomics Research Lab using the Illumina Global Screening Network. GWAS combined meta-analysis, based, among others, on the results from the UroCCR samples.

Clinical Trial Outcome Measures

Primary Measures

  • Identification of new clear cell Renal Cell Carcinoma (ccRCC) risk loci
    • Time Frame: Inclusion Visit
    • From the DNA sample collected at inclusion visit, and the derived Single Nucleotide Polymorphisms (SNPs) genotype data: Association between evaluated genetic variants (SNPs) and renal cell carcinoma will be statistically determined if the p-value is found to be close to or lower than the Genome-wide significance threshold (p <5*10-8).

Participating in This Clinical Trial

Inclusion Criteria

  • Patients over 18,
  • Confirmed cases of renal cell carcinoma (any RCC histology) of European or African origin,
  • Patients included in the UroCCR study,
  • Free, informed, written and signed consent by the participant and the investigator (at the latest on the day of inclusion and before any investigation required by the research) for specific blood collection for the purpose of DNA extraction,
  • Programmed or ongoing management for kidney tumor,
  • Constitutional DNA available (whole blood) for selected cases,
  • Affiliated person or beneficiary of a social security scheme.

Exclusion Criteria

  • Patients below 18,
  • Refusal of consent or participation.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 100 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital, Bordeaux
  • Collaborator
    • National Cancer Institute (NCI)
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Jean-Christophe BERNHARD, +33 5 57 82 12 94, jean-christophe.bernhard@chu-bordeaux.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.